Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors

JAMA Oncology

Volumn 4, Issue 11, 2018, Pages 1589-1593

  Ptashkin, Ryan N ^a   Mandelker, Diana L ^a   Coombs, Catherine C ^a,b   Bolton, Kelly ^a   Yelskaya, Zarina ^a   Hyman, David M ^a,c   Solit, David B ^a,c   Baselga, José ^a,c   Arcila, Maria E ^a   Ladanyi, Marc ^a   Zhang, Liying ^a   Levine, Ross L ^a   Berger, Michael F ^a   Zehir, Ahmet ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BIOASSAY; CANCER TISSUE; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC FINGERPRINTING; GENETIC VARIABILITY; HEMATOPOIESIS; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION; PREVALENCE; RETROSPECTIVE STUDY; SOLID MALIGNANT NEOPLASM; SOMATIC MUTATION; ADOLESCENT; AGED; CHILD; GENETICS; INFANT; NEOPLASM; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIESIS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85056322551     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.2297     Document Type: Conference Paper

References (14)

1. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703-713. doi:10.1038/nm.4333
2. Hartmaier RJ, Albacker LA, Chmielecki J, et al. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Res. 2017;77(9):2464-2475. doi:10.1158/0008-5472.CAN-16-2479
3. Sholl LM, Do K, Shivdasani P, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1 (19):e87062. doi:10.1172/jci.insight.87062
4. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110. doi:10.18632 /oncotarget.4040
5. Hiltemann S, Jenster G, Trapman J, van der Spek P, Stubbs A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res. 2015;25 (9):1382-1390. doi:10.1101/gr.183053.114
6. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181. doi:10.1038/ng.2413
7. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-382.e4. doi:10.1016/j .stem.2017.07.010
8. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498. doi:10.1056/NEJMoa1408617
9. Lee J, Axilbund J, Dalton WB, et al. A polycythemia vera jak2 mutation masquerading as a duodenal cancer mutation. J Natl Compr Canc Netw. 2016;14(12):1495-1498. doi:10.6004/jnccn .2016.0161
10. Li SD, Ma M, Li H, et al. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Med. 2017;9(1):89. doi:10 .1186/s13073-017-0478-1
11. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. doi:10.1200/PO.17.00011
12. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251-264. doi:10 .1016/j.jmoldx.2014.12.006
13. Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131. doi:10.1093/nar/gkw520
14. Weitzel JN, Chao EC, Nehoray B, et al. Somatic TP53 variants frequently confound germ-line testing results [published online November 30, 2017]. Genet Med. doi:10.1038/gim.2017.196